DT02 Rec'd P T0

: 8 FEB 2005 P

#3

I hereby certify that this correspondence is seing deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

INFORMATION DISCLOSURE STATEMENT Patent Application Docket No. GJE-7477 Serial No. 10/517,882

February 15, 2005

David R. Saliwanchik, Patent Attorney

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Not yet assigned

Art Unit

Not yet assigned

Applicant(s):

Michael Harvey Lyne

Serial No.

10/517,882

Filed

December 13, 2004

Conf. No.

Not yet assigned

For

Formulation of Nefopam and its use in the Treatment of Pain

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.56, 1.97, AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national stage application under 35 USC §371. A copy of the international search report and copies of the references cited therein have been made available in the national stage file. However, for the Examiner's convenience, the applicant is attaching herewith a copy of the first page of the cited

foreign patent documents, a full text copy of the literature reference, and the International Search Report. A form PTO/SB/08 listing the references is also attached. In accordance with 37 CFR §1.56, the applicant hereby requests that the references cited in the international search report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100 Fax No.:

352-372-5800

Address:

Saliwanchik, Lloyd & Saliwanchik

A Professional Association

P.O. Box 142950

Gainesville, FL 32614-2950

DRS/la

Attachments: Form PTO/SB/08;

Copies of references listed on Form PTO/SB/08; and

International Search Report/WO

FEB 1 8 2005 W

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box -> +

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/517,882 **Filing Date** December 13, 2004 INFORMATION DISCLOSURE **First Named Inventor** Michael Harvey Lyne STATEMENT BY APPLICANT **Group Art Unit** Not yet assigned **Examiner Name** Not yet assigned (use as many sheets as necessary) GJE-7477 Sheet of 1 **Attorney Docket Number** 

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where	
		Number	Kind Code <sup>2</sup> (if known)	of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	
	U1						
	U2						
	U3		1				
1	U4						

	•			FOREIGN	PATENT DOCMENT	rs		
Examiner Initials*	Cite No. 1	Foreig Office <sup>3</sup>	n Patent Docum	nent Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ <sup>6</sup>
	F1	wo	00/06121		Jago Research AG	02-10-2000		
	F2	wo	02/00195		Epicept Corporation	01-03-2002		
	F3							
	F4							
	F5							T

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	R1	FASMER et al., Antinociceptive Effects of (+-)-, (+)- and (-)- Nefopam in Mice, J. Pharm. Pharmacol. (1987), vol. 39, pages 508-511.				
	R2					

Examiner		 Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.